Not all medical cannabis is the same!
Newswise — MINNEAPOLIS, MN — Children and teens with epilepsy who were treated with pharmaceutical cannabidiol (CBD) had much better seizure control than those who were treated with artisanal CBD, according to a preliminary study to be presented at the American Academy of Neurology’s 72nd Annual Meeting in Toronto, Canada, April 25 to May 1, 2020.
CBD is a cannabis component that relieves stress and anxiety and has anti-seizure properties. It does not produce a “high” like another cannabis component called tetrahydrocannabinol (THC). Pharmaceutical CBD for epilepsy does not have THC. It is FDA approved for use in two severe forms of childhood epilepsy, Dravet syndrome and Lennox-Gastaut syndrome, which do not respond well to other medications. Artisanal CBD is manufactured using varying techniques and contains variable amounts of CBD and THC.
“The use of medical cannabis to treat various medical conditions has grown in recent years. While not always legal, artisanal CBD has been available longer, so some people have been using it to treat epilepsy for years,” said study author Nathan T. Cohen, MD, of Children’s National Hospital in Washington DC, and a member of the American Academy of Neurology. “They may want to reconsider because our research indicates that pharmaceutical CBD may indeed be more effective than artisanal CBD.”
For the study, researchers reviewed the medical charts of 31 children and teens with an average age of 10 who were followed for an average age of one year. All had some form of epilepsy including 32 percent with Lennox-Gastaut syndrome and six percent with Dravet syndrome. Of the group, 22 were taking pharmaceutical CBD and nine were taking artisanal CBD. Researchers recorded medication doses, levels of CBD in the blood, seizure history, and reduction in seizures with medication and side effects.